NASDAQ · SSII

SS Innovations International Inc.

$3.48 -$0.09 (-2.66%) 1D After hours

Key Metrics

$714.47M
Market cap
340.42×
P/E · TTM
$5.98M
Revenue · TTM
$2.10M
Net income
EPS · TTM $0.01
Dividend yield
Free cash flow
Beta · 1Y 0.73
EBITDA · TTM
Gross margin 70.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 17
    From its Mar 18 high, the share price fell 35%.

    Peak close $5.09 on Mar 18; trough close $3.29 on Jun 17. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • Feb 12
    The stock moved +18.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 12
  • Feb 11
    The stock moved -26.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$714.47M
Enterprise value
Shares outstanding200.1M
52-wk range$3.11 – $10.00
Avg volume · 20D52.6K
Net cash
Book value / share$0.29
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About SS Innovations International Inc.
IPO dateJul 9, 2018
Employees483

SS Innovations International Inc is a commercial-stage surgical robotics company.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E340.42
P/S119.46
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.27

Profitability

Gross 70.9%
Operating 37.6%
Net 35.1%
FCF
ROE / ROIC 6.2% · —

Financial Health

Current ratio2.54
Quick ratio1.89
Debt / equity
Debt / EBITDA
Net cash
Working capital$40.22M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

11.7
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$0.27 vs $3.48
Trades 12.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings